AQUESTIVE THERAPEUTICS INC (AQST)
Health Care · Specialty pharmaceutical film formulations and oral solid delivery · NASDAQ
Aquestive develops orally disintegrating film formulations for CNS disorders, acute seizures, and opioid use, leveraging proprietary sublingual and buccal film platforms.
What AQUESTIVE THERAPEUTICS INC does
Aquestive Therapeutics is a specialty pharmaceutical company focused on developing and commercializing proprietary drug formulations using its sublingual and buccal film technologies. The company manufactures and distributes both FDA-approved licensed products (including Suboxone, Emylif, Ondif, and Sympazan) and its pipeline candidates targeting conditions including acute repetitive seizures, ADHD, and ALS. With manufacturing and primary packaging facilities in Portage, Indiana, Aquestive has produced over 2.5 billion doses since inception and maintains cGMP-compliant operations registered with the DEA for controlled substances.
Themes: ["CNS/seizure disorders","Oral disintegrating films","Acute repetitive seizures (ARS)","Opioid use disorder / buprenorphine","Emergency epinephrine","Drug delivery platforms","Orphan drugs"]
Fundamentals
- Price$4.24 as of 2026-07-09 close
- Market cap$535M as of 2026-07-10
- 1-year return+17.1% as of 2026-07-09 close
- Net margin-137.1% as of 2026-07-10
- Gross margin+63.5% as of 2026-07-10
- ROE-21.8% as of 2026-07-10
- Debt / equity4.68 as of 2026-07-10
- Revenue growth (YoY)-7.3% as of 2026-07-10
- Revenue CAGR (3y)-2.2% SEC XBRL
- Beta1.45 as of 2026-07-10
Key risks (from latest filing)
["Revenue declining at 7.3% YoY with negative 137% net margin; company remains unprofitable and dependent on manufacturing and licensing operations to fund R&D pipeline.","Regulatory and commercialization challenges: Libervant FDA approval process and market access remain unclear; multiple pipeline candidates (ADHD, ALS, epinephrine) require successful clinical development and regulatory approval.","Manufacturing and supply chain concentration: Packaging foil supplied by single manufacturer; operations subject to FDA, DEA, and international regulatory inspections; failure to maintain cGMP compliance could result in product seizure, recall, or suspension of operations."]
Competitors & peers
- Indivior Inc. (formerly Reckitt Benckiser) – Suboxone commercialization partner
- Zevra Therapeutics (formerly KemPharm) – CNS and specialty pharma
- Neurelis Inc. – seizure disorder treatments
- Assertio Holdings (Otter Pharmaceuticals) – specialty pharmaceutical licensee
- Cosette Pharmaceuticals – CNS and specialty pharmaceuticals
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.